Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 8.0-65.0,  Migraine Adult ≥ 18 and ≤ 65 years of age females or males; 2. Willing to participate in the study and to complete all study-related procedures, evaluations, and headache diaries; 3. Able to understand, agree to, and sign the study's IRB-approved informed consent form; 4. Has a physician-made diagnosis of Chronic Migraine as defined by the following (a, b, and c): 1. Headache (tension-type and/or migraine) lasting a minimum of 4 hours on ≥15 days per month for at least 3 months and on ≥XX (redacted by sponsor to preserve integrity of study) days in the 30 days prior to the Screening Visit; 2. Headaches on ≥8 days per month for at least 3 months that have fulfilled the following: i. Headaches with at least two of the following unilateral location pulsating quality moderate or severe pain intensity aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs); ii. AND at least one of the following nausea and/or vomiting photophobia and phonophobia; iii. OR headaches that have been treated and relieved by triptan(s) or ergot before the expected development of the symptoms listed in 4.b.i and 4.b.ii above; c. Headaches are not attributed to a substance or substance withdrawal, infection, cranial neuralgias, cluster headaches, autonomic cephalalgias, or cranial, cervical vascular, non-vascular, intracranial homeostasis and psychiatric disorders; 5. If taking medication (prescribed or over-the-counter) for migraine prophylaxis, the medication must have been taken for at least 2 months and the dosage(s) must have been stable for at least 1 month prior to the Screening Visit. There must be no plan to add to, discontinue, or change the dose of these medications throughout the subject's participation in the study; 6. To be eligible for the inpatient Treatment Period: the subject must have recorded in the Headache Diary ≥XX (redacted by sponsor to preserve integrity of study) headaches days (at least 4 hours of continuous head pain per headache day) in the 30 days immediately prior to the Inpatient Treatment Visit (Visit 2); 7. To be eligible for the inpatient Treatment Period: mean head pain severity of ≥XX (redacted by sponsor to preserve integrity of study) and ≤XX (redacted by sponsor to preserve integrity of study) based on the 11-point Numerical Rating Scale (NRS) in the 30 days immediately prior to the Inpatient Treatment Visit (Visit 2) [only data from headache days will be used to calculate the mean head pain severity; missing data on a headache day will be considered to be zero (0) for this calculation]; and 8. To be eligible for the inpatient Treatment Period: The subject must be experiencing head pain on the day of the inpatient Treatment Visit (Visit 2). Subjects may continue the Screening Period for another week if head pain is not present at Visit 2  Any head pain, including coexisting head pain, not attributable to Chronic Migraine as defined in this study's Criterion #4; 2. Any condition that could affect the subject's ability to assess the effect of neurostimulation or in which neurostimulation may be a safety concern, including but not limited to: 1. Known history of epilepsy or recurrent seizures; 2. Known neurogenic and neuromuscular disorders (i.e. myasthenia gravis, multiple sclerosis, autonomic disorders); 3. Uncontrolled diabetes mellitus; 4. Known peripheral neuropathy; 3. History of taking the following medications in the 30 days prior to the Screening Visit: 1. Opioid and opioid-containing medications; 2. Butalbital, butalbital-containing, and barbiturate medications; 3. Systemic corticosteroids (exceptions: acute corticosteroid medication including inhaled therapy (pulmonary), ocular therapy, or non-spinal intra-articular therapy); 4. Urine drug screen that is positive for any of the tested drugs (i.e., cannabis, opiates, barbiturates, amphetamines , benzodiazepines and cocaine) at the Screening Visit (Visit 1) and the Inpatient Treatment Visit (Visit 2); 5. Positive pregnancy test at the Screening Visit (Visit 1) or at the Inpatient Treatment Visit (Visit 2); 6. Known history of cardiac conduction or heart rate abnormalities associated with symptoms; 7. Uncontrolled hypertension; 8. Any tattoos or extensive tissue scarring in the cervical/occipital area; 9. Any active skin lesions, skin damage, broken skin, history of easy bruising or bleeding disorders, or history of surgery and/or trauma in the cervical/occipital area at the time of the Screening Visit; 10. History of occipital nerve (ON) block, peripheral ON stimulation, or botulinum toxin (e.g., Botox) for treatment of headaches within the 90 days prior to the Screening Visit; 11. Radiofrequency rhizolysis involving the occipital nerve or cervical nerves; 12. Surgery involving the occipital nerve or cervical nerves (e.g. neurectomy or rhizotomy), or cervical ganglionectomy; 13. History of craniotomy or intracranial surgery; 14. Presence of metallic implant (e.g., metal pin, staple, clip) in the skull or neck area; 15. Presence of any implanted neuromodulation or cardiac device; 16. Severe or uncontrolled psychiatric disorders (i.e. schizophrenia, depression, anxiety, or at investigator discretion); 17. Any other medical condition, concomitant medication or finding for which, at the discretion of the investigator, the subject should be excluded for reasons of safety or capacity for study compliance; or 18. Participation in any other clinical study (not to registries or survey-only studies) within 30 days or 5 half lives of an investigational drug, whichever is longer, of Visit 1 (Screening Visit) and for the duration of the study